Testing baricitinib after clot removal for certain strokes
Part of Brain & nervous system, Heart & circulation clinical trials.
This study tests whether adding the drug baricitinib to standard clot-removal treatment for a certain type of stroke improves recovery. It aims to see if the drug reduces inflammation in the brain and leads to better outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You had a stroke caused by a blocked large artery in the front part of the brain, confirmed by a scan.
- You received clot removal treatment (endovascular treatment) within 24 hours of stroke symptoms starting.
- Your stroke symptoms must be moderate to severe (NIHSS score above 5) and brain imaging must show enough healthy tissue (ASPECT score above 3).
- You are not allergic to contrast dye or the study drug, and you have no other serious health conditions like bleeding problems, liver infections, or tuberculosis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial checks if adding an interleukin-6 receptor inhibitor (a drug that reduces inflammation) to standard emergency clot removal can improve recovery for people with a severe stroke affecting the back part of the brain (posterior circulation). It is for patients who need urgent treatment within 24 hours of symptom onset.
This trial tests whether baricitinib, a drug that calms inflammation, can reduce lung injury that often happens after a bleeding stroke in the brain. It is for people admitted to the hospital shortly after the bleed and who have no other major lung or immune conditions.
This trial tests whether baricitinib, a pill that lowers inflammation, can also help reduce blood-clotting risk in people with rheumatoid arthritis. It may help if your arthritis is still active despite current treatment, and you have no other major health conditions.
This trial tests if baricitinib, an anti-inflammatory drug, can help people with bleeding in the brain from a head injury. It is for adults with moderate to severe traumatic brain injury who are not immediately having surgery.
This trial tests whether adding a drug called baricitinib to your usual TPO-RA treatment works better than TPO-RA alone for people with ITP who haven't responded enough to TPO-RA. It aims to see if the combination helps raise platelet counts and reduce bleeding risk.
This study tests whether adding a medicine called eptifibatide, which helps prevent blood clots, can improve recovery for people who had a stroke and did not get better enough after standard clot-busting treatment. It may help reduce disability if given soon after the initial treatment.
Hear when a new Acute Ichemic Stroke trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.